



Seville orange juice-felodipine interaction:
Comparison with dilute grapefruit juice
and involvement of furocoumarins
Objective: Our objective was to determine whether Seville orange juice produces a grapefruit juice–like
interaction with felodipine and whether bergamottin, 6′,7′-dihydroxybergamottin, or other furocoumarins
are involved.
Methods: In a randomized three-way crossover design, 10 volunteers received a felodipine 10-mg extended-
release tablet with 240 mL of Seville orange juice, dilute grapefruit juice (that contained equivalent total
molar concentrations of bergamottin plus 6′,7′-dihydroxybergamottin), or common orange juice (negative
control). The pharmacokinetics of felodipine and its dehydrofelodipine metabolite were determined. Juice
concentrations of furocoumarins were measured. CYP3A4 inhibitory activity of newly identified furo-
coumarins was assessed.
Results: The felodipine area under the plasma concentration-time curve was increased by 76% and 93% after
Seville orange juice and grapefruit juice ingestion, respectively, compared with common orange juice. The
effects of Seville orange juice and grapefruit juice were similar in that the felodipine maximum concentra-
tion was augmented while the terminal elimination half-life was unchanged and the dehydrofelodipine area
under the plasma concentration time-curve was increased, but the dehydrofelodipine-felodipine area under
the plasma concentration-time curve ratio was reduced. Bergamottin and 6′,7′-dihydroxybergamottin con-
centrations were 5 and 36 µmol/L, respectively, in Seville orange juice and were 16 and 23 µmol/L, respec-
tively, in dilute grapefruit juice. A newly identified furocoumarin, bergapten, was detected only in Seville
orange juice (31 µmol/L), and it was found to be a mechanism-based inhibitor of recombinant CYP3A4.
Relative to the control, 6′,7′-dihydroxybergamottin (10 µmol/L) inhibited CYP3A4 activity in cultured
intestinal epithelial cells by 93%, whereas bergapten (10 µmol/L) inhibited the activity by only 34%.
Conclusions: Seville orange juice and grapefruit juice interact with felodipine by a common mechanism, which
is probably inactivation of intestinal CYP3A4. Bergamottin and 6′,7′-dihydroxybergamottin may be “marker
substances” in foods for this interaction. The lack of interaction between Seville orange juice and cyclosporine
(INN, ciclosporin) suggests that grapefruit juice may also inhibit intestinal P-glycoprotein, whereas Seville
orange juice may selectively “knock out” intestinal CYP3A4. (Clin Pharmacol Ther 2001;69:14-23.)
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Since the first report that showed that grapefruit juice
increases the oral availability of felodipine,1 the list of
grapefruit juice–drug interactions has been expanded
to more than 20 medications from a diverse range of
therapeutic categories including cardiovascular, anti-
histaminic, gastrointestinal, antiinfective, antilipidic,
central nervous system, and immunosuppressive
agents.2 Each drug that interacts with grapefruit juice
is a substrate for cytochrome P450 (CYP)3A4, the
major CYP isoform expressed in adult human small
intestine3 and liver.4 Because grapefruit juice does not
alter the elimination half-life of drugs administered
orally or intravenously, it is believed that the “grape-
fruit juice effect” is primarily due to inhibition of
intestinal rather than hepatic CYP3A4.5
Grapefruit juice consumption has been shown to
cause a prompt decrease in intestinal CYP3A4
immunoreactive protein in humans; this is consistent
with mechanism-based inactivation of the enzyme fol-
lowed by rapid intracellular degradation.5,6 Moreover,
certain furocoumarins (psoralens) found in grapefruit
juice decreased CYP3A4 immunoreactive protein in
cultured intestinal epithelial (Caco-2) cells 6 or inhib-
ited CYP3A4 catalytic activity, either reversibly or by
mechanism-based inactivation, in human intestinal and
liver microsomes.6-10 Such furocoumarins include berg-
amottin,8 6′,7′-dihydroxybergamottin,6,7 and at least
four others.6,9,10 Because bergamottin and 6′,7′dihy-
droxybergamottin appear to be the most abundant furo-
coumarins in grapefruit juice,6-10 these two substances
may largely account for the grapefruit juice effect. Clin-
ical testing is necessary, however, to identify the
inhibitors of intestinal CYP3A4 in grapefruit juice.11
For the assessment of the effects of bergamottin and
6′,7′-dihydroxybergamottin in vivo, it would be prefer-
able to administer these substances as pure compounds
directly to humans. Unfortunately, the compounds are not
yet approved for human intake. An alternative approach
is to find another food that contains bergamottin and 6′,7′-
dihydroxybergamottin in appropriate concentrations and
then test administer this food with an established drug
probe to determine whether it produces an interaction
similar to that observed with grapefruit juice.
We have determined that juice prepared from Seville
(or sour) oranges contains bergamottin as well as 6′,7′-
dihydroxybergamottin, as previously reported.12 In
addition, Seville orange juice ingestion in 2 healthy vol-
unteers resulted in a dramatic decrease in intestinal
CYP3A4 content,12 which is consistent with results
reported for grapefruit juice.5
We conducted an interaction study with Seville
orange juice and felodipine, the most extensively stud-
ied probe for grapefruit juice–drug interactions.2 The
results were compared with those from grapefruit juice
diluted to contain equivalent total molar concentrations
of bergamottin plus 6′,7′-dihydroxybergamottin (posi-
tive control) and with those from common (or sweet)
orange juice, which neither interacts with felodipine1
nor contains these furocoumarins10,11 (negative con-
trol). Compared with common orange juice, both
Seville orange juice and grapefruit juice similarly
enhanced the oral availability of felodipine and altered
the disposition of its CYP3A4-mediated metabolite,
dehydrofelodipine. Seville orange juice was also found
to contain another furocoumarin, bergapten (5-
methoxypsoralen), which inhibited CYP3A4 but was
less potent than 6′,7′-dihydroxybergamottin. Because
our previous report had shown that Seville orange
juice did not augment plasma cyclosporine (INN,
ciclosporin) concentrations compared with grapefruit
juice,12 this suggests that grapefruit juice may also clin-
ically inhibit intestinal P-glycoprotein–mediated drug
efflux and that Seville orange juice may selectively
“knock out” intestinal CYP3A4.
MATERIALS AND METHODS
Materials
Frozen concentrated grapefruit juice and common
orange juice were obtained from a local market and
diluted to regular strength. Seville orange juice was pre-
pared by squeezing the fresh fruit, which was purchased
from Russo Co (Watertown, Mass) and then sweeten-
ing it with sugar to make it more palatable. The juices
were stored at –20°C until needed for the study. Before
administration, the reconstituted grapefruit juice was
diluted 1.3:1 with water; this resulted in equivalent total
molar concentrations of bergamottin and 6′,7′-dihy-
droxybergamottin as in the Seville orange juice.
Saquinavir and midazolam were gifts from Roche Lab-
oratories (Nutley, NJ). Indinavir was a gift from Merck
and Co (West Point, Pa). Ketoconazole and trolean-
domycin were purchased from Sigma Chemical Co (St
Louis, Mo). Bergamottin was purchased from Indofine
Chemical Co (Somerville, NJ). 6′,7′-Dihydroxyberg-
amottin was generously supplied by Dr Tony Monta-
nari and Mr Bill Widmer (Department of Citrus, Lake
Alfred, Fla). Bergapten (5-methoxypsoralen) and all-
trans retinol were purchased from Aldrich Chemical Co
(Milwaukee, Wis). Human complementary deoxyri-
bonucleic acid (cDNA)–expressed CYP3A4 was pur-
chased from Gentest (Woburn, Mass). J’ sphere ODS-
M80 HPLC columns were obtained from YMC Co, Ltd
(Wilmington, NC). All other chemicals were reagent or
tissue culture grade where appropriate.
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Human subject study
This study was approved by the University of Michi-
gan Institutional Review Board. Ten healthy nonsmok-
ing volunteers (5 men and 5 women) who ranged in age
from 21 to 32 years enrolled in the study after provid-
ing written informed consent. Prestudy evaluations
showed that all of the subjects had normal findings on
physical examination and routine laboratory tests that
included hematology, serum chemistry, and urinalysis.
None of the subjects was taking medications, includ-
ing those available over the counter.
A three-way randomized crossover study design was
used in which each subject received a single oral dose of
a felodipine 10-mg extended-release tablet (Plendil;
Merck & Co, West Point, Pa) with 240 mL of Seville
orange juice, dilute grapefruit juice, or common orange
juice. Peripheral venous blood (7 mL) was collected just
before felodipine and juice administration and at 0.5, 1,
1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, and 24 hours thereafter. Plasma
was separated from blood cells by centrifugation and
stored at –20°C until analysis. The subjects fasted
overnight and were provided lunch and dinner, devoid of
fruits and vegetables, at 4 and 8 hours after dosing,
respectively. All subjects refrained from consuming alco-
hol or caffeine-containing beverages beginning 2 weeks
before the study and during the course of the study. The
interval between each juice treatment was at least 1 week.
Analysis of plasma for felodipine and dehydro-
felodipine
Plasma concentrations of felodipine and its primary
metabolite, dehydrofelodipine, were quantified by a
previously published method with minor modifica-
tions.13 In brief, 200 µL of plasma was extracted with
200 µL of toluene that contained the internal standard,
H165/04 (AB Haessle, Gothenburg, Sweden), by means
of gentle oscillation of the mixture overnight. After cen-
trifugation, 1 µL of toluene extract was introduced by
autoinjector and splitless injection into a dual tapered
deactivated glass insert (Hewlett-Packard Canada,
Toronto, Ontario) to prevent chemical oxidation of
felodipine in the injector port. Chromatography was
accomplished with a Hewlett-Packard 5890 Series II
gas chromatograph equipped with a 63Ni electron cap-
ture detector and a 25 m × 0.32 mm internal diameter
fused silica capillary column coated with the station-
ary phase methyl silicone 0.52 µm (HP-1; Hewlett-
Packard). After purge for 1 minute, the oven tempera-
ture of 90°C was increased 30°C per minute to 180°C,
then 5°C per minute to 260°C for 3 minutes, and then
30°C per minute to a final temperature of 280°C for 5
minutes. The injector port temperature was maintained
at 260°C, and the detector temperature was maintained
at 300°C. The carrier gas was ultrapure helium (column
inlet pressure of 100 kPa), and the makeup gas was
ultrapure nitrogen (60 mL/min). The retention times for
felodipine, dehydrofelodipine, and internal standard
were 20.1, 14.5, and 21.7 minutes, respectively. Each
plasma sample was analyzed in duplicate. The interday
coefficients of variation in plasma felodipine and dehy-
drofelodipine at 5 nmol/L were 3.5% (n = 8) and 9.6%
(n = 8), respectively. The limit of detection for both
felodipine and dehydrofelodipine was 0.5 nmol/L.
Pharmacokinetic analysis
Felodipine and dehydrofelodipine disposition were
assessed with the use of noncompartmental methods. The
terminal elimination rate constant (λz) was determined
with linear regression of at least the last three data points
from the natural logarithm of the plasma concentration-
time curve. The terminal elimination half-life (t1⁄2) was
calculated as ln 2/λz. The zero to 24-hour area under the
plasma concentration-time curve was calculated by the
linear trapezoidal method. Plasma peak concentration
(Cmax) and the time to reach Cmax (tmax) were obtained
directly from the concentration-time profiles.
Statistical analyses
All statistical analyses were performed with the use
of StatView (v5.0.1, SAS Institute, Inc, Cary, NC). Com-
parisons among the three treatment groups were initially
made with ANOVA with repeated measures. For those
analyses for which P was less than .05, comparisons
between Seville orange juice or grapefruit juice and com-
mon orange juice were made with the paired t test and a
Bonferroni-corrected level of significance (P = .025).
Analysis of furocoumarin concentrations in citrus
juices
Bergamottin. An aliquot (1.0 mL) of Seville orange
juice or grapefruit juice used in the study was extracted
thrice with dichloromethane (1.0 mL) by shaking for 1
hour. After centrifugation, the dichloromethane extracts
were combined, the internal standard (all-trans retinol)
was added, and the solution was evaporated to dryness
under a gentle stream of nitrogen in an ice bath. (We
found that drying on ice was essential for recovery of
bergamottin, presumably because of evaporation. Fail-
ure to use this procedure probably accounts for the
lower bergamottin concentrations obtained in our ear-
lier study.5) The residue was dissolved in HPLC mobile
phase (1.0 mL) that consisted of acetonitrile:water
(80:20 vol/vol) and triethylamine (400 µL/L) adjusted
to a pH of 8.0 with 0.01 N sodium hydroxide. An
aliquot of the solution (100 µL) was filtered (0.45 µm),
and a sample (25 µL) was injected onto a 150 × 3.2 mm
Prodigy C18, 5 µm column (Phenomenex, Torrance,
Calif) at a flow rate of 0.7 mL/min. Ultraviolet
absorbance was measured at 310 nm. The retention
times for bergamottin and internal standard were 5.2
and 8.4 min, respectively. The ultraviolet absorbance
profiles (270-350 nm) of the chromatographic peak
from Seville orange juice and grapefruit juice were
identical to that of pure bergamottin standard. Samples
were analyzed in triplicate. The absolute recovery of
bergamottin standard freshly prepared in common
orange juice, which does not contain this substance,
was 91% ± 2%. The standard curve was linear over the
tested range (0-25 µmol/L) and had an intraday coeffi-
cient of variation of 1.7% at 10 µmol/L (n = 4).
6′,7′-Dihydroxybergamottin and bergapten (5-
methoxypsoralen). An aliquot (1.0 mL) of Seville
orange juice or grapefruit juice was extracted once with
dichloromethane (1.0 mL) by shaking for 1 hour. After
centrifugation, a portion (100 µL) of the dichloro-
methane extract was evaporated to dryness under nitro-
gen in an ice bath. The residue was dissolved in HPLC
mobile phase (100 µL) that consisted of acetonitrile:
water (35:65 vol/vol) and triethylamine (400 µL/L)
adjusted to a pH of 3.0 with phosphoric acid. The solu-
tion was filtered (0.45 µm) and a sample (25 µL) was
injected onto a 150 × 3.2 mm Prodigy C18, 5 µm
column at a flow rate of 0.7 mL/min. Ultraviolet
absorbance was measured at 310 nm. The retention
times for 6′,7′-dihydroxybergamottin and bergapten
were 12.3 and 9.5 minutes, respectively. The ultraviolet
absorbance profiles (270-350 mm) for the chromato-
graphic peaks were the same as those for standard 6′,7′-
dihydroxybergamottin and bergapten. The assignment
of the relevant peak to bergapten was further confirmed
by mass spectrometric analysis. Samples were analyzed
in triplicate. The standard curves for 6′,7′-dihydroxy-
bergamottin and bergapten were prepared in common
orange juice, which does not contain these substances,
and coincided with those made directly in HPLC mobile
phase; this demonstrated complete recovery of these
furocoumarins by the extraction procedure. The stan-
dard curves were linear over the tested range (0-50
µmol/L). The intraday coefficients of variation for 6′,7′-
dihydroxybergamottin and bergapten at 25 µmol/L were
5.8% (n = 5) and 2.8% (n = 5), respectively.
Inhibition of cDNA-expressed human CYP3A4 by
bergapten
Saquinavir was chosen as the substrate for these stud-
ies because of its very high turnover, a prerequisite for
the mechanism-based inhibition study. For the reversible
inhibition study, 22 µL of cDNA-expressed human
CYP3A4 (200 pmol/mL) was preincubated with 10 µL
of freshly prepared NADPH-generating system (yield-
ing final concentrations of 1 mmol/L NADP+, 10
mmol/L of glucose-6-phosphate, and 1 U/mL of glucose-
6-phosphate dehydrogenase) and 950 µL of phosphate
buffer (0.1 mol/L of potassium phosphate, 1 mmol/L of
ethylenediaminetetraacetic acid, 5 mmol/L magnesium
chloride, pH 7.4) at 37°C. After 3 minutes, 10 µL of 0.1,
1, or 10 mol/L bergapten was added, followed by 10 µL
of 0.5 mmol/L saquinavir. Bergapten and saquinavir
were both dissolved in acetonitrile:water (1:1 vol/vol).
After an additional 15 minutes, the reaction was stopped
by the addition of 1 mL of ice-cold acetonitrile and
immediate placement of the sample on ice.
For the mechanism-based inhibition study, 25 µL of
cDNA-expressed CYP3A4 (2 nmol/mL) was preincu-
bated with 1.2 µL of NADPH-generating system and 93
µL of phosphate buffer. After 3 minutes, 10 µL of
bergapten was added to achieve final concentrations of
0, 0.1, 1, 10, or 100 µmol/L. After 0, 15, and 30 min-
utes, 10 µL of reaction mixture was removed and added
to 990 µL of a solution composed of 10 µL of 0.5
mmol/L of saquinavir, 10 µL of NADPH-generating
system, and 970 µL of phosphate buffer. The reaction
was terminated after 15 minutes as described previously.
CYP3A4 activity was assessed by measurement of
saquinavir metabolite (M-7) formation as previously
described.14 In brief, internal standard (4 mL of 0.1
µmol/L indinavir in acetonitrile) was added to the incu-
bate and evaporated to dryness with a Savant SpeedVac
system (Holbrook, NY). The remaining residue was
dissolved in 200 µL of acetonitrile:water (1:1 vol/vol).
Two milliliters of acetonitrile was then added. The pre-
cipitate was removed by centrifugation, and the sam-
ples were dried again. The final residue was dissolved
in 15 µL of acetonitrile:water (1:1 vol/vol), and 12 µL
was injected onto a Prism HPLC column (Keystone Sci-
entific Inc, Bellafonte, Pa) connected to a Hewlett-
Packard 1100 series HPLC coupled to a Finnigan ion
trap LCQ mass spectrometer (Thermoquest, San Jose,
Calif). M-7 was eluted with water and 0.1% (vol/vol)
formic acid in acetonitrile. The initial eluant was held
at 90% water for 1 minute. The 0.1% formic acid in
acetonitrile was increased linearly to 65% over 27 min-
utes and then to 90% over 5 minutes. Water was then
increased to initial conditions over 5 minutes. The mass
spectrometer was operated in the positive electrospray
ionization mode with the following conditions: electro-
spray voltage, 5.0 kV; sheath gas, 60 (arbitrary units);
auxiliary gas, 20 (arbitrary units); capillary tempera-
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on laminin-coated inserts and treated with the CYP3A4
inducing agent, 1α,25-dihydroxyvitamin D3, for 2 weeks,
beginning at confluence as previously described.16 Incu-
bation medium (serum-free differentiation medium) was
freshly prepared and kept at 37°C. All compounds were
dissolved as 1000-fold concentrated solutions in either
absolute ethanol (6′,7′-dihydroxybergamottin and keto-
conazole) or dimethyl sulfoxide (midazolam, bergapten,
and troleandomycin). The incubation medium was
spiked with compound(s) or vehicle (0.1% ethanol and
0.2% dimethyl sulfoxide) just before its addition (1.5
mL) to the apical chamber of duplicate cultures; this
was followed by an equal volume of plain incubation
medium to the basolateral chamber. Cell cultures were
first preincubated with either 10 µmol/L of 6′,7′-dihy-
droxybergamottin or bergapten  (10 µmol/L) for 30
minutes and then incubated simultaneously with 6′,7′-
dihydroxybergamottin or bergapten and midazolam (3
µmol/L) for 4 hours. As a positive control, separate cul-
tures were incubated similarly with the selective mech-
anism-based CYP3A4 inhibitor troleandomycin (30
µmol/L). Another set of cultures was also incubated
simultaneously with the reversible CYP3A4 inhibitor
ketoconazole (1 or 10 µmol/L) and midazolam for 2
hours. Medium collected from the apical and basolat-
eral compartments of each culture was analyzed for 1′-
hydroxymidazolam with gas chromatography-mass
spectrometry as previously described.16
RESULTS
Effect of Seville orange juice and dilute grapefruit
juice on oral felodipine disposition
The effect of each juice on mean plasma concentra-
tions and pharmacokinetics of felodipine and its pri-
mary metabolite, dehydrofelodipine, are shown in Fig
1 and Table I. On average, the area under the plasma
concentration-time curve (AUC) and Cmax of felodip-
ine were increased by 76% and 61%, respectively, with
Seville orange juice and by 93% and 88%, respectively,
with grapefruit juice compared with common orange
juice. The differences in AUC and Cmax observed
between Seville orange juice and grapefruit juice were
not significant. The tmax and terminal t1⁄2 of felodipine
were not different among juice treatments. Compared
with common orange juice, the AUC of dehydro-
felodipine was increased by 30% with Seville orange
juice and by 35% with grapefruit juice. Cmax and the
terminal t1⁄2 of dehydrofelodipine were not significantly
different among the juices. The AUC ratios of dehydro-
felodipine to felodipine were significantly lower with
both Seville orange juice and grapefruit juice compared
with common orange juice.
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ture, 225°C; capillary voltage, 25 V; tube offset volt-
age, 36 V; and scan range, 600 to 700 mass-to-charge
ration. Internal standard (indinavir) and M-7 were
extracted from the total ion current with the use of
mass-to-charge ratios of 614.4 and 687.4, respectively.
Inhibition of CYP3A4 by 6′,7′-dihydroxybergamot-
tin and bergapten in Caco-2 cell monolayers
Midazolam was chosen as the substrate for these
studies because (1) we were unable to adequately mea-
sure felodipine metabolites in the incubation medium,
(2) unlike saquinavir, midazolam appears not to be a sub-
strate for P-glycoprotein,15 which is known to be highly
expressed in Caco-2 cells, and (3) midazolam has been
well-characterized as a CYP3A probe in our cell sys-
tem.16-18 The Caco-2 cell subclone P27.7 was cultured
Fig 1. Mean plasma concentration-time profiles for felodip-
ine (A) and dehydrofelodipine (B) in 10 healthy subjects after
administration of a felodipine 10-mg extended-release tablet
with 240 mL of Seville orange juice, dilute grapefruit juice,
or orange juice. Error bars denote standard errors.
A
B
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Furocoumarin concentrations in Seville orange juice
and dilute grapefruit juice
The bergamottin and 6′,7′-dihydroxybergamottin
concentrations were 5 µmol/L and 36 µmol/L, respec-
tively, in Seville orange juice and were 16 µmol/L and
23 µmol/L, respectively, in dilute grapefruit juice. The
bergapten concentration in Seville orange juice was 31
µmol/L. Bergapten was not detected in dilute grapefruit
juice (<1 µmol/L).
Inhibition and inactivation of cDNA-expressed
human CYP3A4 by bergapten
Preliminary kinetic studies showed that metabolism
of saquinavir to its major metabolite, M-7, was
reversibly inhibited by bergapten with a 50% inhibitory
concentration that ranged from 10 to 100 µmol/L (data
not shown). Subsequently, bergapten was shown to pro-
duce time- and concentration-dependent inhibition of
the enzyme (Fig 2).
Inhibition of CYP3A4 activity in Caco-2 cells by
6′,7′-dihydroxybergamottin and bergapten
6′,7′-Dihydroxybergamottin (10 µmol/L) inhibited
midazolam 1′-hydroxylation by 93% compared with
control, whereas the same concentration of bergapten
inhibited this activity by only 34% (Fig 3). Compara-
tively, the CYP3A4 inhibitors troleandomycin (30
µmol/L) and ketoconazole (1 and 10 µmol/L) inhibited
midazolam 1′-hydroxylation by 60% and at least 75%,
respectively. Mean control activities for mechanism-
based inhibitor- and ketoconazole-treated cultures were
95 and 107 pmol per hour per culture, respectively.
DISCUSSION
Felodipine is generally completely absorbed from the
gastrointestinal tract after oral administration.19 However,
it suffers from high presystemic (first-pass) metabolism
sequentially in the gut and then the liver; this results in a
low absolute oral bioavailability, which averages
15%.19,20 Felodipine is biotransformed to a single inac-
tive primary metabolite, dehydrofelodipine,21 and then to
a major secondary metabolite (M3) by CYP3A4.22,23
Compared with common orange juice, Seville orange
juice and grapefruit juice increased the AUCs of felodip-
ine and dehydrofelodipine but decreased the dehydro-
felodipine-felodipine AUC ratio. The decrease in the
metabolite-parent AUC ratio is consistent with inhibition
of the primary metabolic pathway.2 The absolute increase
in the AUC of dehydrofelodipine suggested that a subse-
quent metabolic step was inhibited; this has been supported
for grapefruit juice by measurements that have shown that
M3 was reduced.2,23 Seville orange juice and grapefruit
juice augmented the Cmax but did not change the terminal
t1⁄2 of felodipine. Thus Seville orange juice and grapefruit
juice appear to act by a common mechanism of action,
which is probably inhibition of CYP3A4-mediated first-
pass metabolism in the small intestine. These findings show
that another food substance can cause grapefruit juice-like
drug interactions. Because Seville oranges are used in the
preparation of certain confectioneries, such as marmalades,
it is possible that confectioneries made from this citrus fruit
may also produce a drug interaction. However, it is not
clear at this time whether sufficient concentrations of
CYP3A4 inhibitors are present in those confectioneries to
produce a drug interaction.
Table I. Pharmacokinetics of felodipine and its dehydrofelodipine metabolite after a single dose administration of a
felodipine 10-mg extended-release tablet with 240 mL of Seville orange juice, dilute grapefruit juice, or common
orange juice.
Seville orange juice Dilute grapefruit juice Orange juice
Felodipine
AUC0-24 (nmol/L · h) 68.1 ± 8.7* 74.7 ± 8.8* 38.6 ± 5.5
Cmax (nmol/L) 11.9 ± 1.9* 13.9 ± 1.7* 7.4 ± 1.4
tmax (h) 4.4 ± 0.5 3.4 ± 0.4 3.4 ± 0.3
Terminal t1⁄2 (h) 5.9 ± 0.5 7.7 ± 1.3 8.8 ± 1.5
Dehydrofelodipine
AUC0-24 (nmol/L · h) 81.0 ± 9.5* 84.4 ± 8.3* 62.4 ± 6.5
Cmax (nmol/L) 16.7 ± 1.6 17.0 ± 1.5 14.4 ± 1.5
tmax (h) 3.9 ± 0.3* 2.8 ± 0.3 2.8 ± 0.2
Terminal t1⁄2 (h) 10.9 ± 3.6 11.5 ± 2.6 11.3 ± 2.1
Dehydrofelodipine to felodipine
AUC0-24 1.3 ± 0.1* 1.2 ± 0.1* 1.8 ± 0.2
AUC0-24, AUC from 0 to 24 hours.
Data are presented as mean values ± standard error of the mean. Comparisons are between Seville orange juice or dilute grapefruit juice and common orange juice.
*P < .025.
The Seville (or sour) orange is considered to be an
ancient fruit whose existence was documented before
the birth of Christ.24 In contrast, the grapefruit is rela-
tively new; it was first found growing in the West Indies
in the mid-1700s. The grapefruit is believed to have
evolved from the pummelo, either as a spontaneous
mutation or an inadvertent hybrid with the common
orange.24,25 This is supported by the observation that
juice from the pummelo contains several of the same
furocoumarins as grapefruit juice and potently inhibits
CYP3A4 activity in vitro.10 Additional citrus fruits,
including the Seville orange, may also have evolved
from the pummelo.25 This raises the possibility that the
CYP3A4 inhibitors in the pummelo, grapefruit, and
Seville orange are in other citrus fruits and that this type
of food-drug interaction could be more common than
previously thought. Indeed, juice from the Sweetie fruit
has recently been shown to contain these furocoumarins
and to inhibit CYP3A4 activity in vitro.10
In a grapefruit juice–felodipine interaction study in
which small bowel biopsy specimens were obtained
from healthy subjects, grapefruit juice effectively
decreased enterocyte CYP3A4 protein levels.5 Hepatic
CYP3A4 activity, as measured by the intravenous ery-
thromycin breath test, was not altered. The decrease in
enterocyte CYP3A4 protein by grapefruit juice was not
accompanied by a change in CYP3A4 messenger
ribonucleic acid content; this suggests that the effect of
grapefruit juice was acceleration of the degradation of
enterocyte CYP3A4 protein rather than decreasing of
its synthesis. It was concluded that substances in grape-
fruit juice are probably metabolized by CYP3A4 to
reactive intermediates that inactivate the enzyme,5,6 a
process termed mechanism-based inactivation. The
inactivated and structurally modified CYP3A4 presum-
ably undergoes rapid proteolysis within the enterocyte.
Because the mechanism-based inhibitors bergamot-
tin and 6′,7′-dihydroxybergamottin were present in both
Seville orange juice and grapefruit juice, the results of
this study support our hypothesis that these chemicals
are involved in the clinical interaction and that they
might be used as marker substances to predict this type
of interaction with other foods. This possibility is sup-
ported by other findings. In a previous clinical investi-
gation, grapefruit juice was first separated by high-
speed centrifugation and ultrafiltration into two frac-
tions (supernatant and particulate) that contained dif-
ferent concentrations of these two substances.11 Each
fraction was then administered with felodipine to test
for an interaction. The supernatant fraction, which con-
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Fig 2. Mechanism-based inhibition of cDNA-expressed
human CYP3A4 by bergapten. Expressed CYP3A4 was
preincubated with an NADPH-generating system and with 0,
0.1, 1, 10, or 100 µmol/L of bergapten for 0, 15, and 30 min-
utes. Ten µL of the reaction mixture were removed and
diluted 1:100 with phosphate buffer that contained 5 µmol/L
of saquinavir and NADPH-generating system. Relative
CYP3A4 activity (saquinavir oxidation) was determined as
the percentage of control (based on peak areas). Each bar rep-
resents the mean value of 2 or 3 incubations. Error bars
denote standard deviations.
Fig 3. Effects of the CYP3A4 inhibitors ketoconazole (keto)
and troleandomycin (TAO) and the furocoumarins 6′,7-dihy-
droxybergamottin (DHB) and bergapten (berg) on midazo-
lam 1′-hydroxylation in Caco-2 cells expressing CYP3A4.
Percent control activity was calculated as the total amount
(apical + basolateral) of 1′-hydroxymidazolam formed in
inhibitor or furocoumarin-treated cultures divided by total 1′-
hydroxymidazolam formed in vehicle-treated cultures. Each
bar represents the mean of duplicate cultures. Mean control
activity for TAO, DHB, and bergapten-treated cultures was
95 pmol/h, and that for ketoconazole-treated cultures was 107
pmol/h. BLD, below limit of detection.
tained no measurable bergamottin (<1 µmol/L) but con-
tained 20 µmol/L of 6′,7′-dihydroxybergamottin, sig-
nificantly augmented the AUC of felodipine compared
with water. However, the effect was less pronounced
compared with whole grapefruit juice. The rediluted
particulate fraction, which contained 30 µmol/L of
bergamottin and 6 µmol/l of 6′,7′-dihydroxybergamot-
tin, also increased the AUC of felodipine to a greater
extent than the supernatant fraction. This is consistent
with the conclusion that both bergamottin and 6′,7′-
dihydroxybergamottin are present in sufficient concen-
trations in grapefruit juice to produce in vivo inhibition
of intestinal CYP3A4 and an interaction with felodip-
ine. However, it now seems likely that additional furo-
coumarins contribute significantly to the effects of the
whole juices.6,9,10 For example, it has recently been
reported that grapefruit juice and Seville orange juice
contain the furocoumarins termed GF-I-1, GF-I-4, GF-
I-5, and GF-I-6.10 Each of these can produce both
reversible and mechanism-based inhibition of CYP3A4
in human liver microsomes at concentrations approxi-
mately the same as those found in the juices.10 In addi-
tion, GF-I-1 (also called FC726), has been shown to
potently inhibit CYP3A4 and cause loss of CYP3A4
immunoreactive protein in cultured cells.6 All of these
furocoumarins are highly lipophilic and are concen-
trated primarily in the particulate fraction of grapefruit
juice.10 In this study and our previous studies,26 these
newly characterized furocoumarins were not measured,
and thus their contribution to the observed effects in
vivo is unknown.
We determined that Seville orange juice also con-
tained another furocoumarin, bergapten. Bergapten pro-
duced mechanism-based inhibition of recombinant
CYP3A4 and inhibited CYP3A4-mediated midazolam
1′-hydroxylation in intestinal cell culture at concentra-
tions less than those measured in Seville orange juice.
However, the in vitro potency of bergapten was about
one third of that observed with 6′,7′-dihydroxyberg-
amottin. Thus the contribution of bergapten to the in
vivo interaction observed between Seville orange juice
and felodipine is uncertain. Nevertheless, bergapten
may be another furocoumarin capable of producing a
clinical drug interaction.
In a recent study that was similar in design to the cur-
rent investigation, grapefruit juice enhanced the oral
availability of cyclosporine, whereas Seville orange
juice did not.12 This lack of effect by Seville orange
juice occurred despite a marked decrease in enterocyte
CYP3A4 content that was measured in 2 subjects.
Therefore these results further support the conclusion
that the extent of metabolism of cyclosporine by intesti-
nal CYP3A4 is generally small.27 It also follows that
inhibition of intestinal CYP3A4 cannot be the main
mechanism whereby grapefruit juice enhances the oral
availability of cyclosporine.
P-glycoprotein is an efflux pump located in the
apical membrane (brush border) of enterocytes.28 P-
glycoprotein functions to pump many xenobiotics,
including cyclosporine, from the interior of the entero-
cyte back into the gut lumen.29 Felodipine, however,
does not appear to be a substrate for this pump.30 The
effect of grapefruit juice on P-glycoprotein mediated
drug efflux has been investigated in two studies in which
polarized human intestinal cells were used.30,31 In
one study, grapefruit juice inhibited P-glycoprotein–
mediated efflux,31 whereas in the other it appeared to
activate P-glycoprotein–mediated efflux.30 The authors
of the latter work,30 however, have recently stated that
their findings may have been the result of equipment-
generated artifacts (Leslie Z. Benet, PhD, personal
communication, September 2000). Therefore the results
of our study and in vitro findings support the concept
that grapefruit juice may inhibit both intestinal-medi-
ated CYP3A4 metabolism and P-glycoprotein efflux of
drugs. Seville orange juice, on the other hand, may
more selectively knock out enteric CYP3A4.
Because bergamottin and 6′,7′-dihydroxybergamottin
were measured in both Seville orange juice and grape-
fruit juice, and because bergapten was present in only
Seville orange juice, these three substances are unlikely
to be clinically important inhibitors of intestinal P-
glycoprotein. Naringin concentrations in the Seville
orange juice and grapefruit juice used in the current
study were measured according to a previously pub-
lished method11 and were found to be 1644 µmol/L and
439 µmol/L, respectively, which also eliminates this
substance (a flavonoid) as an important inhibitor of P-
glycoprotein in vivo. These conclusions are further sup-
ported by in vitro findings that show that bergamottin,
6′,7′-dihydroxybergamottin,12,32 and naringin32 did not
inhibit P-glycoprotein–mediated efflux in cultured cells.
In summary, Seville orange juice and grapefruit juice
produced a pharmacokinetic interaction with the drug
probe felodipine, most probably as a result of inactiva-
tion of intestinal CYP3A4. Both bergamottin and 6′,7′-
dihydroxybergamottin appear to be clinically important
inhibitors in these juices, although other furocoumarins,
including the newly identified substance bergapten,
may be involved. Grapefruit juice may also inhibit
intestinal P-glycoprotein–mediated drug efflux activ-
ity, although the responsible substances in grapefruit
juice appear to be different from those identified as
inactivating CYP3A4. Because Seville orange juice
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may selectively knock out intestinal CYP3A4 activity,
it might be used to estimate the relative contribution of
the intestine to the overall first-pass metabolism of a
CYP3A4 substrate.
We thank Dr Kenneth E. Thummel and Ms Justina Calamia
(Department of Pharmaceutics, University of Washington, Seattle,
Wash) for the gas chromatography-mass spectrometry analysis of the
Caco-2 cell samples for 1′-hydroxymidazolam.
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